ECO Animal Health gets regulatory go-ahead in Argentina

The AIM-traded firm said its patented antimicrobial Aivlosin is used for the treatment of a variety of economically important respiratory and enteric diseases in pigs and poultry.

It said the authorisations, which were for the use of Aivlosin 625 mg/g water soluble granules for both pigs and poultry, would allow ECO to start selling Aivlosin in Argentina for the medication of drinking water for the treatment of infections caused by mycoplasma in poultry laying eggs for human consumption, with a zero day drug withdrawal period for eggs.

The new treatments met all the latest guidelines for the responsible use of antimicrobials, the board claimed.

It added that, with global concerns about the use of antibiotics in food production animals, Aivlosin was administered under the control of veterinarians, available by prescription only and had low, highly effective therapeutic dose rates, a short treatment duration and a zero day drug withholding period.

“We are extremely pleased to receive these marketing authorisations for Aivlosin in Argentina, the third largest egg and second largest pork producing country in South America,” commented ECO Animal Health chairman Peter Lawrence.